Skip to main content

Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three Targeted Assays.

Barthelemy D, Lescuyer G, Geiguer F, Grolleau E, Gauthier A, Balandier J, Raffin M, Bardel C, Bouyssounouse B, Rodriguez-Lafrasse C, Couraud S, Wozny AS, Payen L

Publication: Cancers (Basel) (2023) • Vol 15PMID: 36900363View on PubMed

Purpose

The purpose of this paper was to compare the sensitivity and specificity of three next generation sequencing (NGS)-based methods (a custom assay, OncoBEAM and SeqSensei) for the detection of cell-free DNA (cfDNA) mutations in the plasma of patients with non-small cell lung cancer (NSCLC).  

 

Conclusion

Of the 212 plasma specimens evaluated, 123 had one or more cfDNA mutations identified by one or more of the technology platforms investigated, with no mutations identified in the remaining 89 specimens. The mutations identified included 116 EGFR, 25 KRAS, 14 PIK3CA, 10 BRAF and 50 “other gene” mutations in the 123 plasma specimens.  The cfDNA input amount was not standardized across assays and was generally higher for the custom assay compared to the other NGS assays. When only mutations detected by both OncoBEAM and Plasma-SeqSensei SOLID CANCER IVD kit (SeqSensei)  platforms were considered, the sensitivity and specificity of the OncoBEAM assay for detection of mutations found using SeqSensei were 84% and 94%, respectively. Concordance between the OncoBEAM and SeqSensei NGS assays was observed for75% of cases. Non-concordance was attributed to results below the sensitivity limit for the SeqSensei assay (7% of cases) or the OncoBEAM assay (5% of cases), and undetected gene mutations with the OncoBEAM assay (13% of cases). The mutations with discordant finding often had a mutant allele frequency (MAF) <0.15% or were in regions with low coverage in the OncoBEAM assay. The MAF was strongly correlated between SeqSensei and OncoBEAM NGS assays.

When only mutations detected by both the custom assay and SeqSensei platforms were considered, the sensitivity and specificity of the custom NGS assay for detection of mutations identified with the SeqSensei assay was 83% and 76%, respectively. Concordance between the custom assay and the SeqSensei assay was observed in 68% of cases; discordance between the assays was attributable to the limit of detection of the custom NGS assay (11% of cases), the limit of detection of the SeqSensei assay (5% of cases), and because mutations were only detected by the custom NGS assay (16% of cases). Much of the discordance occurred for mutations with a MAF<1.0%. The MAF was modestly correlated between the SeqSensei and custom NGS assays (R2=0.46, P<0.001). It is important to note that the custom NGS assay detected additional mutations in TP53, ERBB2, and MET genes, which the authors stated had a prognostic and/or predictive value.

Studies (1)

Purpose

The purpose of this study was to compare the sensitivity and specificity of three NGS-based methods for the detection of cfDNA mutations in plasma of patients with non-small cell lung cancer (NSCLC).  Blood was collected from 212 patients with NSCLC and plasma was isolated by double centrifugation (centrifugation speed and duration not specified). Plasma was stored at -80°C until cfDNA extraction with the QIA-amp Circulating Nucleic Acid Kit. cfDNA was quantified using the Qubit dsDNA HS Assay Kit. A custom sequencing library containing 77 genes was prepared from 209 cfDNA extracts using custom capture technology from SOPHiA GENETICS and pair-end sequenced on a NextSeq 550 machine. Additionally, 36 alterations and 7 deletions in the EGFR gene were detected in cfDNA isolated from 130 specimens using the OncoBEAM EGFR V2 Kit which uses the BEAMing (amplification, emulsion PCR with magnetic bead bound primers, hybridization to fluorescent probes, and detection by flow cytometry) method to detect mutations. Finally, mutations in parts of exons of BRAF (exons 11 and 15), EGFR (exons 18, 19, 20, and 21), KRAS (exons 2, 3, and 4), and PIK3CA (exons 2, 3 and 4) were detected in all 212 specimens using the NGS-based Plasma-SeqSensei SOLID CANCER IVD Kit.

Summary of Findings

Of the 212 plasma specimens evaluated, 123 specimens had one or more mutations identified by one or more of the technology platforms, with no mutations identified in the remaining 89 specimens. The mutations identified included 116 EGFR, 25 KRAS, 14 PIK3CA, 10 BRAF and 50 “other gene” mutations.  The input amount of cfDNA was not standardized across assays and was generally higher for the custom NGS-based assay. When mutations were limited to those detected by both OncoBEAM and SeqSensei platforms, the sensitivity and specificity of the OncoBEAM assay for detection of mutations found using SeqSensei assay were 84% and 94%, respectively. Concordance between OncoBEAM and SeqSensei assays was observed in 75% of cases, with mutations in 7% of cases missed due to the sensitivity limit of the SeqSensei assay, 5% of cases missed due to the sensitivity limit of the OncoBEAM assay, and 13% of cases because gene mutations were not detected with theOncoBEAM assay. Mutations with discordant finding often had a MAF <0.15% or were in regions with low coverage in the OncoBEAM assay. The MAF was strongly correlated between SeqSensei and OncoBEAM assays (R2=0.74, P<0.001)

When mutations were limited to those detected by both the custom NGS and SeqSensei assays, the sensitivity and specificity of the custom NGS assay for detection of mutations found using SeqSensei were 83% and 76%, respectively. Concordance between the custom NGS assay and SeqSensei was observed in 68% of cases, with discordance attributable to the limit of detection of the custom NGS assay (11% of cases), the limit of detection of the SeqSensei assay (5% of cases), and because mutations were only detected by the custom NGS assay (16% of cases). Much of the discordance occurred for mutations with a MAF<1.0%. The MAF was modestly correlated between SeqSensei and the custom NGS assay (R2=0.46, P<0.001). It is important to note that the custom NGS assay detected additional mutations in TP53, ERBB2 and MET genes not included in SeqSensei which the authors state have prognostic and/or predictive value.

  • Biospecimens

    FluidPlasma
  • Preservation Types

    Frozen
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    DNAFlow cytometry
    DNANext generation sequencing
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Next generation sequencing SpecificTechnology platform
    Custom NGS assay
    OncoBEAM EGFR V2 kit (BEAMing assay)
    Plasma-SeqSensei SOLID CANCER IVD kit (NGS assay)